Bli medlem
Bli medlem

Du är här


Swedish Orphan Biovitrum AB (publ) : Sobi publishes Annual Report 2014

Swedish Orphan Biovitrum AB (publ) (Sobi) today published its Annual Report
for 2014, themed "We have a story to tell", on the company's

The report summarises 2014, which was a pivotal year for the company. It
encompasses Sobi's vision to pioneer a world in which patients with rare
diseases are diagnosed at birth and receive effective and sustainable
therapy, enabling them to live full and healthy lives. Sobi aims to develop
new medicinal products and therapies and, through close dialogue with
relevant stakeholders such as authorities, healthcare providers and patient
organisations, to build a sustainable model for ensuring that these products
reach patients over a lifetime.

Sobi's Annual Report includes interviews with key external stakeholders,
giving their perspective on the development of the pharmaceutical industry
and how it is to live with a rare disease, respectively.


About Sobi

Sobi is an international specialty healthcare company dedicated to rare
diseases. Our mission is to develop and deliver innovative therapies and
services to improve the lives of patients. The product portfolio is primarily
focused on Haemophilia, Inflammation and Genetic diseases. We also market a
portfolio of specialty and rare disease products for partner companies across
Europe, the Middle East, North Africa and Russia. Sobi is a pioneer in
biotechnology with world-class capabilities in protein biochemistry and
biologics manufacturing. In 2014, Sobi had total revenues of SEK 2.6 billion
(USD 380 M) and about 600 employees. The share (STO: SOBI) is listed on
NASDAQ OMX Stockholm. More information is available

For more information please contact

Media relations Investor relations
Oskar Bosson Jörgen Winroth
Head of Communications VP, Head of Investor Relations
T: +46 70 410 71 80 T: +1 347-224-0819, +1

Sobi Annual Report 2014 ENG


This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Swedish Orphan Biovitrum AB (publ) via Globenewswire


Författare Hugin

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.